Farxiga: FDA Approval and Dosage Information

FDA Approval Information

The FDA approval for Farxiga (dapagliflozin) signifies a significant milestone as it expands its use beyond type 2 diabetes to include reducing the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure‚ regardless of left ventricular ejection fraction status.​ AstraZeneca‚ the company behind Farxiga‚ ensures that the drug meets the necessary safety and efficacy standards before being authorized for use by the FDA.​ Stay informed about the latest updates and recommendations regarding the Farxiga FDA approval.​

Dosage Information

Farxiga (dapagliflozin) is available in two strengths⁚ 5 mg and 10 mg.​ The recommended starting dosage is 5 mg once daily‚ taken in the morning with or without food.​ For individuals requiring additional glycemic control‚ the dosage may be increased to 10 mg. Patients are advised to undergo kidney testing before initiating Farxiga.​ Always follow the guidance provided by healthcare professionals regarding the appropriate dosage of Farxiga for your condition.

Additional Dosage Guidelines

For patients with normal or mildly impaired kidney function‚ the recommended starting dose of Farxiga is 5 mg taken once daily.​ This can be adjusted to 10 mg for those requiring better glycemic control.​ Individuals with more severe kidney impairment may need special consideration when determining the appropriate dosage. Consult healthcare providers for personalized dosage recommendations based on your specific medical history and needs.​

Warnings and Precautions

When considering the use of Farxiga (dapagliflozin)‚ it is crucial to be aware of potential warnings and precautions.​ Individuals with a history of hypersensitivity reactions to dapagliflozin or any components of Farxiga should avoid its usage.​ Before initiating treatment‚ assess volume status and correct any volume depletion.​ It is recommended to monitor renal function regularly.​ Always adhere to healthcare provider guidance regarding the safe use of Farxiga and be vigilant for any signs of adverse reactions.

Recent Changes and Updates

As of the latest available information‚ Farxiga (dapagliflozin) has been FDA approved for new indications to reduce the risk of cardiovascular death‚ hospitalization for heart failure‚ and urgent heart failure visits in adults with heart failure.​ Stay informed about any recent changes or updates related to the FDA approval status and recommended usage of Farxiga.​

Generic Name and Company

Farxiga is the brand name for the generic drug dapagliflozin‚ which is manufactured by AstraZeneca. This medication is commonly used for the treatment of type 2 diabetes‚ heart failure‚ and chronic kidney disease.​ It is essential to follow the prescribing information provided by healthcare professionals when using Farxiga to ensure safe and effective use.